The lack of predictive animal models for neuropsychiatric diseases is arguably the biggest single factor stifling early drug development in the field. To kick-start discovery for diseases such as autism, schizophrenia and depression, stakeholders will need to abandon traditional models, build on emerging genetic findings and capitalize on new capabilities in stem cell technology, imaging and computational modeling.